Artiva Biotherapeutics (ARTV) Operating Leases (2023 - 2025)
Historic Operating Leases for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $8.5 million.
- Artiva Biotherapeutics' Operating Leases fell 2366.49% to $8.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year decrease of 2366.49%. This contributed to the annual value of $10.6 million for FY2024, which is 2062.18% down from last year.
- According to the latest figures from Q3 2025, Artiva Biotherapeutics' Operating Leases is $8.5 million, which was down 2366.49% from $9.6 million recorded in Q2 2025.
- In the past 5 years, Artiva Biotherapeutics' Operating Leases registered a high of $15.5 million during Q2 2024, and its lowest value of $8.5 million during Q3 2025.
- Its 3-year average for Operating Leases is $11.3 million, with a median of $10.6 million in 2024.
- As far as peak fluctuations go, Artiva Biotherapeutics' Operating Leases plummeted by 2062.18% in 2024, and later tumbled by 3835.17% in 2025.
- Artiva Biotherapeutics' Operating Leases (Quarter) stood at $13.3 million in 2023, then decreased by 20.62% to $10.6 million in 2024, then decreased by 19.4% to $8.5 million in 2025.
- Its last three reported values are $8.5 million in Q3 2025, $9.6 million for Q2 2025, and $10.3 million during Q1 2025.